

1 Dysbiosis and structural disruption of the respiratory microbiota in 2 COVID-19 patients with severe and fatal outcomes

3

4 Alejandra Hernández-Terán¹, Fidencio Mejía-Nepomuceno¹, María Teresa Herrera², Omar Barreto³,
5 Emma García³, Manuel Castillejos⁴, Celia Boukadida⁵, Margarita Matias-Florentino⁵, Alma Rincón-
6 Rubio⁵ Santiago Avila-Rios⁵, Mario Mújica-Sánchez⁶, Ricardo Serna-Muñoz¹, Eduardo Becerril-
7 Vargas⁶, Cristobal Guadarrama-Pérez⁷, Víctor Hugo Ahumada-Topete⁴, Sebastián Rodríguez¹, José
8 Arturo Martínez-Orozco⁶, Jorge Salas-Hernández⁸, Rogelio Pérez-Padilla¹, Joel Armando Vázquez-
9 Pérez^{1*}.

10 Affiliations

11 ¹Departamento de Investigación en Tabaquismo y EPOC. Instituto Nacional de Enfermedades Respiratorias
12 Ismael Cosío Villegas, INER.

13 ²Departamento de Investigación en Microbiología. Instituto Nacional de Enfermedades Respiratorias Ismael
14 Cosío Villegas, INER.

15 ³Coordinación de Atención Médica. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
16 INER.

17 ⁴Departamento de Unidad de Epidemiología Hospitalaria e Infectología. Instituto Nacional de Enfermedades
18 Respiratorias Ismael Cosío Villegas, INER.

19 ⁵Centro de Investigación en Enfermedades Infecciosas, CIENI. Instituto Nacional de Enfermedades
20 Respiratorias Ismael Cosío Villegas, INER.

21 ⁶Laboratorio de Microbiología. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
22 INER.

23 ⁷Servicio de Urgencias Médicas. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas,
24 INER.

25 ⁸Dirección General INER. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER.

26

27 ***Corresponding author:** Joel Armando Vázquez-Pérez, joevazpe@gmail.com

28 Keywords:

29 SAR-CoV-2, respiratory microbiota, severity, COVID-19, dysbiosis

30 **Abstract**

31 COVID-19 outbreak has caused over 3 million deaths worldwide. Understanding disease
32 pathology and the factors that drive severe and fatal clinical outcomes is of special
33 relevance. Studying the role of the respiratory microbiota in COVID-19 is particularly
34 important since it's known that the respiratory microbiota interacts with the host immune
35 system, contributing to clinical outcomes in chronic and acute respiratory diseases. Here,
36 we characterized the microbiota in the respiratory tract of patients with mild, severe, or
37 fatal COVID-19, and compared with healthy controls and patients with non-COVID-19-
38 pneumonia. We comparatively studied the microbial composition, diversity, and microbiota
39 structure across study groups and correlated the results with clinical data. We found
40 differences in diversity and abundance of bacteria between groups, higher levels of
41 dysbiosis in the respiratory microbiota of COVID-19 patients (regardless of severity level),
42 differences in diversity structure among mild, severe, and fatal COVID-19, and the
43 presence of specific bacteria that correlated with clinical variables associated with
44 increased mortality risk. Our data suggest that host-related and environmental factors could
45 be affecting the respiratory microbiota before SARS-CoV-2 infection, potentially
46 compromising the immunological response of the host against disease and promoting
47 secondary bacterial infections. For instance, the high levels of dysbiosis coupled with low
48 microbial structural complexity in the respiratory microbiota of COVID-19 patients,
49 possibly resulted from antibiotic uptake and comorbidities, could have consequences for the
50 host and microbial community level. Altogether, our findings identify the respiratory
51 microbiota as a potential factor associated with COVID-19 severity.

52

53

54

55

56

57 **Introduction**

58 The Coronavirus Disease 2019 (COVID-19) outbreak, declared a pandemic by the World
59 Health Organization on the 11th of March 2020, is caused by the Severe Acute Respiratory
60 Syndrome Coronavirus 2 (SARS-CoV-2). As of May 2021, SARS-CoV-2 has infected
61 more than 150 million people and caused over 3 million deaths worldwide¹. COVID-19
62 shows a wide spectrum of clinical manifestations ranging from asymptomatic infection and
63 mild respiratory symptoms to severe pneumonia and death,^{2,3} which has been related to
64 demographic factors and comorbidities. To date, it has been shown that the aberrant
65 immune response against SARS-CoV-2 antigens is critically involved in severe clinical
66 outcomes and other secondary inflammatory conditions that remain after COVID-19^{3,4}.

67 Studying the role of the human microbiota in COVID-19 is particularly relevant since it's
68 known that the respiratory microbiota interacts with the host immune system, contributing
69 to clinical outcomes in chronic and acute respiratory diseases⁵. The respiratory microbiota
70 has a central role in shaping pulmonary immunity by boosting innate and adaptive immune
71 responses. Suggesting that host immunity is regulated by interactions with the bacterial
72 communities in the respiratory tract.

73 Some studies suggest that the interactions between microorganisms and the host immune
74 system are species-specific, denoting that even minor variations in the diversity and
75 composition of the microbiota could have significant consequences on host's health⁶. For
76 COVID-19, severe to fatal clinical outcomes are often associated with the presence of
77 comorbidities that are known to display altered (dysbiotic) microbiota⁷ (e.g., diabetes type
78 II, obesity, age, and heart disease). Furthermore, in a wide range of microbiome-associate
79 diseases (MADs), dysbiosis is a common feature that can impact disease progression^{8,9}.

80 Nonetheless, few studies characterizing the respiratory microbiota in COVID-19 and the
81 presence of dysbiosis are available to date ¹⁰⁻¹⁴ .

82 To gain insight into the association between respiratory microbiota and COVID-19
83 severity; we characterized the microbiota in the respiratory tract of patients with mild,
84 severe, or fatal COVID-19, and compared with healthy controls and patients with non-
85 COVID-19-pneumonia. We comparatively studied the microbial composition, diversity,
86 and microbiota structure across study groups and correlated the results with clinical data.
87 These analyses let us detect 1) differences in abundance of bacteria between groups, 2)
88 higher levels of dysbiosis in the respiratory microbiota of COVID-19 patients, 3)
89 differences in diversity structure among mild, severe, and fatal COVID-19 microbiota, and
90 4) the presence of specific bacteria that correlated with clinical variables associated with
91 increased mortality risk. In summary, our results demonstrate an increasing dysbiosis of the
92 respiratory tract microbiota in COVID-19 patients coupled with a continuous loss of
93 microbial complexity structure from mild to fatal COVID-19 that could potentially alter
94 clinical outcomes. Altogether, our findings identify the respiratory microbiota as a potential
95 factor associated with COVID-19 severity.

96

97

98

99

100

101 **Results**

102 **Study participants**

103 Since our sample set consists of upper and lower respiratory tract samples, we kept only
104 upper respiratory samples for the main diversity and statistical analyses. Overall, a total of
105 95 samples were analyzed (mild COVID-19 = 37, severe COVID-19 = 27, fatal COVID-19
106 = 19, healthy control = 7, and non-COVID-19-pneumonia = 5).

107 Demographic data, health-related characteristics, and symptomatology are described in
108 Table 1. Overall, 52 patients were male (54.7%) with a median age of 45 years old (IQR:
109 21). Regarding health conditions, 58.2% of the participants presented at least one
110 comorbidity, being DM2 (17%), hypertension (17%), smoking (17%), and obesity (35%)
111 the most widely represented in the cohort. The median days of symptom onset were seven,
112 and 52.6% of the individuals received antibiotic treatment before hospitalization.
113 Furthermore, we found important associations between some health/demographic
114 characteristics and severity. For instance, patients with fatal COVID-19 were
115 predominantly male (73.6%, $p = 0.01$), significantly older (median= 58, $p = 6.57e-07$), with
116 higher BMI (median= 30.4, $p = 0.05$), and most of them received previous antibiotic
117 treatment (78.9%, $p = 0.002$) compared with patients with severe and mild COVID-19.
118 Also, a higher number of days after symptoms onset was found in the non-COVID-19-
119 pneumonia group (median= 10, $p = 0.01$).

120

121

122 **The respiratory microbiota composition differs among severity levels for COVID-19**
123 **and controls**

124 From the 95 analyzed samples belonging to the upper respiratory tract, we identified a total
125 of 4514 Amplicon Sequence Variants (ASVs). Regarding the analysis of the relative
126 abundance (Fig. 1A), p_Firmicutes, p_Bacteroidetes, and p_Proteobacteria were the most
127 dominant phyla among our severity groups and controls. In general, these phyla are present
128 in all group samples but there are changes in the relative abundance associated with the
129 disease severity. In general, we found p_Firmicutes, p_Actinobacteria, p_TM7, and p_SR1
130 significantly increased in COVID-19 patients, while p_Bacteroidetes and p_Proteobacteria
131 were found significantly decreased (Supplementary Table S2).

132 The relative abundance analysis at the genus level revealed genera that significantly differ
133 among COVID-19 patients and controls (Fig. 1B, Supplementary Table S2). In general, we
134 found g_Veillonella, g_Staphylococcus, g_Corynebacterium, g_Neisseria,
135 g_Actinobacillus, and g_Selenomonas significantly enriched in the COVID-19 patients but
136 reduced in the healthy controls. In contrast, we found g_Haemophilus and g_Alloiococcus
137 enriched in the healthy controls but reduced in the COVID-19 patients. Moreover, there
138 were differences in the abundance of some genera among the severity levels for COVID-
139 19. For example, g_Streptococcus and g_Staphylococcus showed an increasing abundance
140 from mild to fatal COVID-19. In contrast, g_Haemophilus and g_Actinomyces showed the
141 opposite pattern, where the highest abundance is associated with mild COVID-19 and the
142 lowest with the fatal COVID-19. Also, we found g_Corynebacterium highly abundant only
143 in severe COVID-19, while g_Actinobacillus were found highly abundant only in fatal
144 COVID-19.

145 Besides, we compared the most abundant phyla for severe and fatal COVID-19 in the upper
146 and lower respiratory tract (Supplementary Figure S3). In particular, we found differences
147 at phylum and genus level. For instance, for severe COVID-19 patients, we found a higher
148 abundance of p_Firmicutes, g_*Neisseria*, and g_*Haemophilus* in the lower respiratory tract.
149 In contrast, we found p_Actinobacteria, p_Fusobacteria, p_SR1, and
150 g_*Staphylococcus* enriched in the upper respiratory tract. For fatal COVID_19 patients, we
151 found p_Proteobacteria, g_*Streptococcus*, g_*Neisseria*, and g_*Capnocytophaga* enriched in
152 the lower respiratory tract albeit, in the upper respiratory tract, we found p_TM7, p_SR1,
153 g_*Corynebacterium*, and g_*Staphylococcus*. Nonetheless, it is worth mentioning that
154 regardless of the differences found in phyla abundance, we found no differences in beta
155 diversity analyses.

156 *Alpha diversity*

157 Respecting diversity calculated with the Shannon-Wiener index (Fig. 2), we found healthy
158 controls as the most diverse group and the non-COVID-19-pneumonia group ($p < 0.05$) as
159 the less diverse. Although among severity groups the differences are not considerable, we
160 did find significant differences among severe and fatal COVID-19 groups ($p < 0.05$).

161 *Beta diversity*

162 The beta diversity analyses showed differences in the microbiota composition among
163 severity levels for COVID-19 and controls (Fig. 3A-B, Supplementary Table S4).

164 Particularly, the PCoA analysis (Fig. 3A) showed differences among severity levels and
165 control groups. Such differences are supported by the PERMANOVA result ($F = 2.7, p =$
166 0.007). Additionally, the dysbiosis analysis in terms of the Ružička metric allowed us to

167 determine that the microbiota associated with COVID-19 (regardless of severity level)
168 showed significantly higher levels of dysbiosis compared with healthy control
169 (Supplementary Table S4).

170 The LefSe analysis allowed the identification of differentially abundant taxa associated
171 with the compared groups (Fig. 3B). We observed that all the COVID-19 severity groups
172 and the two control groups showed differentially abundant taxa or biomarkers. In particular,
173 for mild COVID-19, we found *g_Prevotella melaninogenica* and *g_P. pallens*,
174 *g_Veillonella parvula*, *g_Neisseria subflava*, *g_Fusobacterium*, and *g_Actinomyces* as
175 highly abundant. For severe COVID-19, we found *g_Megasphaera* and *o_CW040* as the
176 most prevalent. In the case of fatal COVID-19, *g_Rothia dentocariosa*, *g_Streptococcus*
177 *infantis*, and *g_Veillonella dispar* were the most significant. Moreover, the higher number
178 of differentially abundant taxa were found to be associated with healthy controls (e.g.,
179 *g_Streptococcus*, *g_Flavobacterium*, and *g_Oribacterium*, and *f_Veillonellaceae*). Finally,
180 for the non-COVID-19-pneumonia group, we found *g_Corynebacterium*, *g_Prevotella*
181 *nigrescens*, *g_Capnocytophaga*, and *f_Enterobacteriaceae* as the most abundant.

182 **Clinical variables associated with mortality risk correlate with specific microbial** 183 **groups in the respiratory microbiota**

184 The Kaplan-Meier survival curves led to the detection of clinical variables that significantly
185 correlated with survival probability (Fig. 4-A). For instance, we found that APACHE
186 scores above 8 points, levels of Blood Urean Nitrogen (BUN) lower than 40 mg/dl,
187 lymphocytes under $1.25 \times 10^3/\mu\text{l}$, myoglobin above 110ng/ml, troponin above 3.5ng/ml, and
188 urea under 80mg/dl represent high risk by negatively affecting survival probability.

189 The Lefse analysis allowed us to detect bacteria either enriched or depleted in the different
190 risk factor groups for the analyzed variables (Fig. 4-B). We found *g_Neisseria subflava*
191 depleted in the high-risk samples for troponin and APACHE. Moreover, *g_Veillonella*
192 *dispar* interestingly was found depleted in the low-risk samples for APACHE, BUN,
193 myoglobin, and urea. Nonetheless, we also found some bacterial groups that are constantly
194 enriched in the samples with high-risk for several clinical variables. For instance,
195 *g_Corynebacterium* was found enriched in the high-risk samples for lymphocytes count
196 and urea, while *g_Actinomyces* was enriched in BUN and urea. Besides, four ASV's of
197 *Prevotella* genus (*g_Prevotella melaninogenica*; *g_Prevotella*; *g_[Prevotella]*;
198 *g_[Prevotella]_s*) were found significantly enriched in the high-risk samples for
199 myoglobin, BUN, troponin, and lymphocytes count.

200 **The structure of the respiratory microbiota is different among severity levels for** 201 **COVID-19**

202 The network analysis for the microbiota associated with the severity levels for COVID-19
203 revealed differences at a structural level (Fig. 5A-B). The graphic representation of the
204 networks showed a different arrangement for each one and a continuum of loss of
205 complexity across COVID-19 severity groups (from mild to fatal) (Fig. 3A). Particularly,
206 the network of the microbiota associated with mild COVID-19 was the largest and more
207 connected one (nodes= 148, edges = 4758) compared to severe COVID-19 (nodes=84,
208 edges=688) and fatal COVID-19 (nodes=74, edges=75). Interestingly, in patients with fatal
209 outcome, the network of the respiratory microbiome was highly disaggregated and poorly
210 connected with multiple isolated nodes (nodes = 74, edges = 75).

211 The metric calculation of the networks illustrates that the topology associated with each
212 COVID-19 severity level is different (Figure 3B, Supplementary Table S5). For instance,
213 the mild COVID-19 network exhibited the highest values for the average number of
214 neighbors, density, and clustering. In contrast, the severe disease network was characterized
215 by greater centralization, and heterogeneity, while the fatal disease network showed the
216 highest values for diameter, characteristic path length, and connected components.

217

218

219

220

221

222

223

224

225

226

227

228

229

230 Discussion

231 COVID-19 pandemic has raised major scientific efforts to identify factors associated with
232 the different disease severity outcomes. Here, we characterized the respiratory microbiota
233 as a potential factor affecting severity outcome for COVID-19. We assessed differences in
234 diversity and structure of the microbial communities associated with a large cohort of
235 patients and linked the results to clinical variables to get insights into the mechanisms by
236 which the microbiota may impact host response against the disease.

237 As well in recent studies investigating COVID-19 etiology³, we found that demographic
238 and health-related factors showed strong associations with severity. Male sex, high values
239 for BMI, age above 50 years old, and previous antibiotic treatment were significantly
240 associated with fatal COVID-19 patients (Table 1), thus potentially favoring the
241 development of a fatal state of the disease.

242 Likewise in previous work exploring COVID-19 associated respiratory microbiota^{14,15}, we
243 found significantly lower microbial diversity in the microbiota of COVID-19 patients than
244 in the healthy controls (Fig.1A). This result is relevant since, in general, more diversity is
245 correlated with a better response of the microbial systems against perturbation (e.g.,
246 disease). A more diverse microbiota can persist after disease (e.g., by functional
247 redundancy) or recovers to an earlier state (e.g., resilience)¹⁶ having direct consequences
248 on the host's health⁸.

249 Furthermore, we found differences in the abundance of some bacteria among our study
250 groups (Fig. 1A, Supplementary Table S2). In particular, as well as other respiratory dis-
251 eases¹⁷, we observed an increased ratio of p_Firmicutes/p_Bacteroidetes in COVID-19

252 patients. p_Firmicutes was detected highly abundant while p_Bacteroidetes where particu-
253 lar decreased in the microbiota associated to COVID-19 patients. This is of particular inter-
254 est since, in murine models, it has been proven that p_Bacteroidetes can down-regulate the
255 expression of ACE2¹⁸. Although the correlation was observed in gut microbiota, the par-
256 ticular low abundance of members of such phylum in severe and fatal patients in this work
257 opens the question about if this process could also take place in the respiratory tract.

258

259 Regarding the analysis at the genus level, the most significant differences were found in
260 potentially pathogenic bacteria (Fig. 1B, Supplementary Table S2). We identified a gradual
261 increase of g_Streptococcus from mild to fatal COVID-19. Although g_Streptococcus is
262 usually a commensal member of the respiratory microbiota, it can become pathogenic in the
263 face of environmental disturbs. In higher abundance, such genus it has been linked to viral
264 acute respiratory infections^{19,20}. Furthermore, genera such as g_Veillonella,
265 g_Staphylococcus, and g_Actinomyces also exhibited high abundance in the different sever-
266 ity levels for COVID-19. Specifically, g_Veillonella and g_Actinomyces have been found
267 as opportunistic pathogens in COVID-19²¹. Moreover, g_Staphylococcus is one of the
268 most common causal agents of secondary infections in respiratory diseases such as influen-
269 za²².

270

271 Regarding beta diversity, we found some differences among the analyzed groups. For
272 instance, we observed in the PCoA analysis that the samples belonging to severe and fatal
273 COVID-19, as well as to the non-COVID-19-pneumonia group, are more alike in terms of
274 microbial composition than the healthy controls and the mild COVID-19 patients (Fig. 2A).

275 Moreover, our dysbiosis analysis let us detect that the microbiota of COVID-19 showed
276 higher levels of dysbiosis than the healthy control (Supplementary Table S4). Several
277 MADs exhibit this behavior in which microbiota instability (dysbiosis) is present not by the
278 dominance of one or a few bacteria but by a higher heterogeneity/stochasticity of microbial
279 groups ⁹.

280 Dysbiosis implies a disruption in the bidirectional interactions between the host immune
281 system and the microbial communities, potentially altering functions provided by these
282 communities and reshaping the whole host-microbiota interaction ^{8,23}. It has been shown
283 that microbiota stability is a hallmark of the health and homeostasis of the host ^{6,8,20}. For
284 instance, some reports suggest that there is a homeostatic mechanism that keeps lung
285 epithelium in an interferon prime state with antiviral activity against other respiratory
286 infections such as influenza. This particular antiviral response is stimulated by specific
287 pathogen-associated molecular patterns (PAMPs) that are induced by the microbial
288 communities ²⁴. In this sense, the modification of microbial communities (e.g., dysbiosis)
289 showed in COVID-19 patients could be modifying the specific PAMPs that stimulate this
290 homeostatic antiviral response, allowing for better conditions for respiratory virus infection,
291 encompassing SAR-CoV-2.

292 A common question when studying MADs is whether dysbiosis enhances disease or is
293 caused by it. For COVID-19, the clinical outcome is highly correlated with comorbidities
294 such as hypertension, diabetes, and obesity ⁷, which are often associated with dysbiosis in
295 the gut microbiota ²¹. This remark, together with the highly distributed antibiotic uptake in
296 COVID-19 patients (53.6% in our cohort, regardless of severity), merits a reflection on the
297 possibility that most of the patients could be dysbiotic at the time of the disease. In other

298 respiratory diseases such as COPD and asthma, it has been shown that dysbiosis in the
299 respiratory microbiota can lead to a deregulated immune response, increasing inflammatory
300 processes^{6,8,25}. Considering that aberrant immune responses are determinant in COVID-19
301 progression, a previous dysbiotic respiratory microbiota could be affecting disease
302 progression.

303 The LefSe analysis (Fig. 3B) shows a differential abundance of microbial groups. For
304 example, we found that most of the groups associated with the healthy controls belong to
305 the so-called "normal" respiratory microbiota (e.g., *g_Streptococcus*, *g_Oribacterium*, and
306 *f_Veillonellaceae*)²⁶. In contrast, when we look at the results of the microbiota associated
307 with COVID-19 and non-COVID-19-pneumonia groups, other potentially pathogenic
308 microbial groups appear. In particular, in patients with non-COVID-19-pneumonia we
309 found bacteria associated with nosocomial infections such as *g_Corynebacterium*^{27,28}. For
310 mild COVID-19, we found some microbial groups associated with disease or bacteremia
311 like *g_Prevotella melaninogenica*, *g_V. parvula* and *g_Neisseria subflava*^{7,28}. For the case
312 of severe COVID-19, we found *g_Megasphaera* that has been associated with the risk of
313 ventilator-associated pneumonia (VAP) in other studies characterizing COVID-19
314 microbiota¹². Additionally, we found *g_Rothia dentocariosa* highly abundant in deceased
315 patients. This bacteria has been found as the causal agent of secondary pneumonia in H1N1
316 infection²² and more recently have been associated with disease progression in previous
317 studies characterizing COVID-19 respiratory microbiota, being proposed as a biomarker for
318 the disease^{13,14}.

319 From a clinical standpoint, it makes sense that a higher mortality predictor such as
320 APACHE score correlates with low survival in COVID-19 patients. Other clinical factors

321 such as BUN or urea have also been used as severity markers in respiratory diseases such as
322 community-acquired pneumonia²⁹. Acknowledging that multiple pathophysiological
323 considerations still unexplained in SARS-CoV-2 infection, and the multisystemic
324 involvement that has been observed in COVID-19³⁰, biochemical markers of organ
325 dysfunction such as lymphopenia, elevated myoglobin, and troponin serum levels as those
326 found in this study, can help predict mortality in these patients³¹. Although the association
327 of these factors with specific microbial groups in the respiratory tract has not been
328 previously reported, the findings in this study open the path to further study the relationship
329 between respiratory microbiota and clinical outcomes. The identification of pathogenic
330 bacteria such as *g_Actinomyces*, *g_Prevotella* and *g_Corynebacterium* in association with
331 two or more clinical factors further supports the current research line trying to correlate the
332 gut-lung axis with pulmonary disease³².

333 Recent studies, as well as this work, suggest that particularly anaerobic bacteria inhabiting
334 the respiratory tract may be involved in COVID-19 pathogenesis and host immune system.
335 In particular, *g_Prevotella* has been found to increase in studies with patients with severe
336 disease and have been co-related to cardiac injury and higher risk mortality^{31,33}. In this
337 work, we found this specific genus associated with four clinical variables that predict
338 mortality in patients with COVID-19 (Fig. 4A). This finding is of special interest
339 considering previous evidence of *g_Prevotella* enhancing a Th17 mediated response
340 through IL-8, CCL20, and IL-6 secretion^{33,34}; both the Th17 response and its cytokines are
341 currently associated with the host's immune response to SARS-CoV-2³⁵.

342 Finally, the co-occurrence arrangement of ecological networks lets us identify structural
343 patterns that reflect variations in the biological properties of the microbial communities

344 associated with COVID-19. For instance, we found that all networks are distinguishable in
345 terms of topological metrics such as density, clustering, and heterogeneity. It is worth
346 mentioning that such metrics are potentially related to the stability of the systems likewise
347 to other ecological properties such as resilience and redundancy³⁶. In particular, we found a
348 striking pattern of reduction of structural complexity from mild to fatal COVID-19. The
349 loss of complexity is showed by a reduction in the number of nodes, edges (connections),
350 density, and clustering. Passing through from a highly connected and dense network (mild
351 COVID-19) to a highly disaggregated, unconnected network (fatal COVID-19) (Fig. 5AB,
352 Supplementary Table S5).

353 Those structural changes can lead to the generation of hypotheses regarding consequences
354 at the microbial community level. For instance, changes in structural patterns could
355 potentially be reflected in alterations in the ecological relationships among microorganisms.
356 A common feature in MADs is that commensal/neutral bacteria can become pathogenic at
357 the face of disease²¹. That is the case of bacteria such as *g_Prevotella*, *g_Veillonella*,
358 *g_Streptococcus*, *g_Actinomyces*, or *g_Megasphaera*, which have been found as
359 opportunistic pathogens in other studies characterizing COVID-19 microbiota^{12,19-21} and
360 that were also found in this work (severe and fatal associated microbiota (Fig. 2B)). The
361 shift from neutral to deleterious interactions in specific bacteria could be the result of a loss
362 of interactions that maintain the function and stability of the microbial systems. Which in
363 turn, could cause an exacerbate growth of microbial groups potentially pathogenic, but also
364 the depletion of beneficial bacteria, altering the whole environment and possibly
365 compromising functions provided by the microbiota to the host.

366

367 **Conclusions**

368 Overall, this work provides insights into the role of the respiratory microbiota in COVID-
369 19 disease. Our data suggest that host-related and environmental factors could be affecting
370 the respiratory microbiota before SARS-CoV-2 infection, potentially compromising the
371 immunological response of the host against disease and promoting secondary bacterial
372 infections. For instance, the high levels of dysbiosis coupled with poor microbial structural
373 complexity in the respiratory microbiota of COVID-19 patients, possibly resulted from
374 antibiotic uptake and comorbidities, could have consequences at the host and microbial
375 community level. On the one hand, increased dysbiosis in diseased patients could be
376 modifying the PAMPs that stimulate a homeostatic antiviral response, allowing for better
377 conditions for SAR-CoV-2 replication. Additionally, the loss of structural complexity may
378 provoke the appearance of opportunistic pathogens that, through ecological competition,
379 can cause the depletion of beneficial bacteria and promote secondary bacterial infections
380 that worsen the clinical outcome. In summary, the findings of this work contribute to
381 understand the pathology of COVID-19 by identifying the respiratory microbiota as a
382 potential factor affecting disease outcome. Further investigations looking for the specific
383 mechanisms by which dysbiotic microbiota in the respiratory tract compromise
384 immunological responses against virus infections are needed.

385

386

387

388 **Methods**

389 **Ethics statement**

390 The Science, Biosecurity and Bioethics Committee of the Instituto Nacional de
391 Enfermedades Respiratorias revised and approved the protocol and the consent procedure
392 given by the participants or their legal guardians (B-0520). Additionally, the Institution
393 requested an informed consent for the recovery, storage, and use of the biological remnant
394 to research purposes.

395 **Study design**

396 As part of a surveillance program at the Instituto Nacional de Enfermedades Respiratorias
397 Ismael Cosío Villegas (INER), 115 initial respiratory samples (oropharyngeal swabs,
398 nasopharyngeal swabs, and tracheal aspirates) were collected between March 2020 and
399 October 2020. Additionally, we included seven subjects without respiratory symptoms and
400 negative SARS-CoV-2 RT-PCR test (healthy), and five patients with pneumonia that were
401 hospitalized but negative to SARS-CoV-2 (non-COVID-19-pneumonia control group).
402 Patients with COVID-19 were classified into three mutually exclusive categories of
403 severity: a) mild COVID-19 (patients with moderate symptoms that did not required
404 hospitalization), b) severe COVID-19 (patients that required hospitalization and were
405 subject to Invasive Mechanical Ventilation (IMV)), and c) fatal COVID-19 (deceased
406 patients). Overall, a total of 37 patients with mild disease, 38 with severe disease and, 40
407 with fatal outcome were included in the study.

408

409 **DNA extraction and 16S rRNA sequencing**

410 Respiratory samples, either nasopharyngeal swabs, oropharyngeal swabs or tracheal
411 aspirates, for all 127 patients were collected and centrifugated for 15 min at 4,800 g, and
412 the pellet was used for DNA extraction. DNA was extracted using the QIAmp Cador
413 Pathogen Mini Kit extraction (Qiagen N.V., Hilden, Germany) according to the
414 manufacturer's instructions. V3-V4 16S rRNA region was amplified by PCR using the
415 primers reported by Klindworth et al (2013)³⁷ (for more information see Supplementary
416 Material S1). Library preparation was done according to the Illumina 16S metagenomic
417 sequencing protocol with few modifications. Briefly, 16S amplicons were purified with the
418 DNA clean & concentrator kit (Zymo Research, Irvine Cal., USA). Dual indices and
419 Illumina sequencing adapters were attached in a second PCR step using Nextera XT Index
420 Kit V2 (Illumina, San Diego Cal., USA). Finally, amplicons were purified, pooled in
421 equimolar concentrations, and sequenced in a MiSeq Illumina instrument generating
422 paired-end reads of 250bp.

423 **Sequence data processing**

424 Illumina raw sequences were processed with QIIME2 (v.2020.8)³⁸. Sequences denoising,
425 quality filtering, and chimera checking were performed with DADA2³⁹. From the original
426 number of reads (13,533,440), we kept a total of 9,499,204 with an average of 73,637
427 sequences per sample. The Amplicon Sequence Variants (ASVs) were aligned with
428 MAFFT⁴⁰ and used to construct a phylogeny with fasttree2⁴¹. ASVs taxonomy was
429 assigned with the Näive Bayes classifier *sklearn*⁴² using the Greengenes 13.8 database⁴³.

430 All ASVs identified as mitochondria (N=10), and chloroplast (N=32) were removed. Raw
431 data were deposited in the NCBI Sequence Read Archive (SRA) (PRNAJ726205).

432 **Diversity, compositional, and statistical analyses**

433 Since our sample set contains both upper (Oropharyngeal swabs [OPS], Nasopharyngeal
434 swabs [NPS]) and lower (Tracheal aspirates [TA]) respiratory tract samples, and it is
435 known that these sites vary in microbial composition, we used only upper respiratory
436 samples for the main analyses. After this process we kept a total of 95 samples (mild
437 COVID-19 = 37, severe COVID-19 = 27, fatal COVID-19 = 19, healthy control = 7, and
438 non-COVID-19-pneumonia = 5). We also characterized TA samples to compare levels of
439 severity in the microbiota of the upper and lower respiratory tract.

440 *Composition analyses*

441 In order to determine if the samples associated with different severity levels and controls
442 differed in the most abundant phylum and taxa, we plotted a bar graph by using the median
443 and standard error of each taxon in the analyzed groups. Besides, we performed a Kruskal-
444 Wallis test to determine if there were any significant differences followed by a paired
445 Wilcoxon rank-sum test in the "vegan" R package ⁴⁴.

446 *Alpha diversity*

447 We calculated the Shannon-Wiener diversity index with the "microbiome" R package ⁴⁵. To
448 detect potential differences among groups we conducted a Wilcoxon rank-sum test in the
449 "vegan" R package ⁴⁴.

450 *Beta diversity*

451 We carried out a Principal Coordinates Analysis (PCoA) with weighted UniFrac distance at
452 ASV level in the "phyloseq" R package ⁴⁶. Potential differences in beta diversity were
453 addressed with a Permutational Analysis of Variance (PERMANOVA) with 999
454 permutations performed with the "vegan" R package ⁴⁴. Additionally, we tested for
455 dispersion and stochasticity as a proxy of dysbiosis in microbial communities ⁴⁷. For this,
456 we calculated the Ružička similarity metric in the "CommEcol" R package ⁴⁸ and
457 performed a Wilcoxon rank-sum test to detect potential statistical differences between
458 healthy controls and diseased groups in their intra-treatment sample similarities. Dysbiosis
459 was assumed when the similarities between the healthy microbiota samples were
460 significantly higher than the similarities between the diseased microbiota samples ⁹.

461 Finally, to detect differentially abundant taxa associated with severity levels and controls,
462 we performed a Linear Discriminant Analysis (LDA) with effect size (LefSe) at the ASV
463 level using the web-based tool MicrobiomeAnalyst ⁴⁹. Only taxa with a LDA score higher
464 than 1.5 and a p -value < 0.01 were used. All diversity and statistical analyses were
465 performed in *R* program (v.1.3.1) ⁵⁰.

466 **Clinical data analyses**

467 In order to analyze the clinical data associated with our patient's cohort, we transform each
468 clinical variable into a binomial category according to its data distribution. We used cut-
469 points based on the 25 and 75 percentiles for each variable. For example, for a given
470 variable, we classified all samples with values above or equal to the 75 percentile as "1",
471 and all samples with values under the 75 percentile as "2". Subsequently, we constructed
472 Kaplan-Meier survival curves in SPSS Statistics (version 21) (Chicago, Illinois, USA) by

473 using the hospitalization days as time variable, the mortality status (either deceased or
474 alive) as a dependent variable, and the specific clinical qualitative variables as exposure
475 variable. Only those curves statistically ($p < 0.05$) and biologically meaningful were
476 retained for subsequent analyses.

477 Also, to determine if there were differentially abundant bacteria associated with the several
478 risk factors for the clinical variables obtained from the Kaplan-Meier curves, we performed
479 a second LefSe analysis. From this result, only taxa with a LDA score higher than 1.5 and a
480 p -value < 0.01 were used.

481 **Network structure inference**

482 We inferred the network structure for the microbiota associated with the different severity
483 levels. Network calculation was performed in the software CoNet³⁶ by using read counts
484 summarized at the ASV level. One network was constructed for each severity level
485 (samples; mild COVID-19: 37, severe COVID-19: 27, and fatal COVID-19: 19). Only co-
486 occurrences statistically supported by the three tested methods (Pearson, Spearman, and
487 Kendall) with a correlation > 0.85 and a p -value < 0.01 were established as edges in the
488 graphs. Also, we applied a multi-test correction using the Benjamini-Hochberg procedure.
489 Network visualization was performed in Cytoscape (v. 3.8.2)⁵¹.

490 To further characterize the structure, we computed metrics of the topology of each network
491 using the NetworkAnalyzer plug-in in Cytoscape⁵¹ and visualized them with a spider chart
492 constructed in R program.

493

494

495

496 REFERENCES

- 497 1. WHO. Weekly epidemiological update on COVID-19-11 May 2021. *11 May* 32 (2021). Available at:
498 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021)
499 2021. (Accessed: 12th May 2021)
- 500 2. Baloch, S., Baloch, M. A., Zheng, T. & Pei, X. The coronavirus disease 2019 (COVID-19) pandemic.
501 *Tohoku J. Exp. Med.* **250**, 271–278 (2020).
- 502 3. Sharma, R., Agarwal, M., Gupta, M., Somendra, S. & Saxena, S. K. Clinical Characteristics and
503 Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). in *Coronavirus*
504 *Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics* (ed. Saxena, S.
505 K.) 55–70 (Springer Singapore, 2020). doi:10.1007/978-981-15-4814-7_6
- 506 4. Yeoh, Y. K. *et al.* Gut microbiota composition reflects disease severity and dysfunctional immune
507 responses in patients with COVID-19. *Gut* 1–9 (2021). doi:10.1136/gutjnl-2020-323020
- 508 5. Man, W. H., De Steenhuijsen Piters, W. A. A. & Bogaert, D. The microbiota of the respiratory tract:
509 gatekeeper to respiratory health. *Nat. Rev. Microbiol.* **15**, 259–270 (2017).
- 510 6. Budden, K. F. *et al.* Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir.*
511 *Med.* **7**, 907–920 (2019).
- 512 7. Bao, L. *et al.* Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. *Front. Microbiol.*
513 **11**, 1–13 (2020).
- 514 8. Li, K. J. *et al.* Dysbiosis of lower respiratory tract microbiome are associated with inflammation and
515 microbial function variety. *Respir. Res.* **20**, 1–16 (2019).
- 516 9. Ma, Z. (Sam). Testing the Anna Karenina Principle in Human Microbiome-Associated Diseases.

- 517 *iScience* **23**, 101007 (2020).
- 518 10. Han, Y., Jia, Z., Shi, J., Wang, W. & He, K. The active lung microbiota landscape of COVID-19
519 patients. *medRxiv* (2021).
- 520 11. Shen, Z. *et al.* Genomic diversity of SARS-CoV-2 in COVID-19 patients. *J. Infect. Dis.* 1–27 (2020).
- 521 12. Lloréns-Rico, V. *et al.* Mechanical ventilation affects respiratory microbiome of COVI-19 patients
522 and its interactions with the host. *medRxiv* (2021).
- 523 13. Marotz, C. *et al.* Microbial context predicts SARS-CoV-2 prevalence in patients and the hospital built
524 environment. *medRxiv* (2020). doi:10.1101/2020.11.19.20234229
- 525 14. Xu, R. *et al.* Temporal dynamics of human respiratory and gut microbiomes during the course of
526 COVID-19 in adults. *medRxiv* 6-
- 527 15. Zhang, H. *et al.* Metatranscriptomic characterization of COVID-19 identified a host transcriptional
528 classifier associated with immune signaling. *Clin. Infect. Dis.* (2020).
- 529 16. Allison, S. D. & Martiny, J. B. H. Resistance, resilience, and redundancy in microbial communities.
530 *Light Evol.* **2**, 149–166 (2009).
- 531 17. Wang, B., Yao, M., Lv, L., Ling, Z. & Li, L. The Human Microbiota in Health and Disease.
532 *Engineering* **3**, 71–82 (2017).
- 533 18. Geva-Zatorsky, N. *et al.* Mining the human gut microbiota for immunomodulatory organisms. *Cell*
534 **168**, 928–943 (2017).
- 535 19. Teo, S. M. *et al.* The infant nasopharyngeal microbiome impacts severity of lower respiratory
536 infection and risk of asthma development. *Cell Host Microbe* **17**, 704–715 (2015).
- 537 20. Lynch, S. V. The lung microbiome and airway disease. *Ann. Am. Thorac. Soc.* **13**, S462–S465 (2016).
- 538 21. Ferreira, C., Viana, S. D. & Reis, F. Is gut microbiota dysbiosis a predictor of increased susceptibility
539 to poor outcome of COVID-19 patients? An update. *Microorganisms* **9**, 1–12 (2021).

- 540 22. Prakash, R., Sangeetha, S., Lakshminarayana, S. A. & Sunil Kumar, D. C. Secondary Pneumonia due
541 to *Rothia mucilaginosa* in H1N1 patient. *J. Int. Med. Dent.* **3**, 58–60 (2016).
- 542 23. Kumar, P. & Chander, B. COVID 19 mortality: Probable role of microbiome to explain disparity.
543 *Med. Hypotheses* **144**, 110209 (2020).
- 544 24. Bradley, K. C. *et al.* Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from
545 Influenza Virus Infection. *Cell Rep.* **28**, 245–256.e4 (2019).
- 546 25. Khatiwada, S. & Subedi, A. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible
547 link and implications. *Hum. Microbiome J.* **17**, 100073 (2020).
- 548 26. Huffnagle, G. B., Dickson, R. P. & Luckacs, N. W. The respiratory tract microbiome and lung
549 inflammation: a two-way street. *Mucosal Immunol.* **10**, 299–306 (2017).
- 550 27. Renom, F. *et al.* Respiratory infection by *Corynebacterium striatum*: Epidemiological and clinical
551 determinants. *New Microbes New Infect.* **2**, 106–114 (2014).
- 552 28. Zimmermann, A. *et al.* Atopobium and *Fusobacterium* as novel candidates for sarcoidosis-associated
553 microbiota. *Eur. Respir. J.* **50**, 1–10 (2017).
- 554 29. Lim, W. S. *et al.* British Thoracic Society guidelines for the management of community acquired
555 pneumonia in adults: Update 2009. *Thorax* **64**, (2009).
- 556 30. Bohn, M. K. *et al.* Pathophysiology of COVID-19: Mechanisms underlying disease severity and
557 progression. *Physiology* **35**, 288–301 (2020).
- 558 31. Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular system. *Nat. Rev.*
559 *Cardiol.* **17**, 259–260 (2020).
- 560 32. Fromentin, M., Ricard, J. D. & Roux, D. Respiratory microbiome in mechanically ventilated patients:
561 a narrative review. *Intensive Care Med.* **47**, 292–306 (2021).
- 562 33. Chakraborty, S. Metagenome of SARS-Cov2 patients in Shenzhen with travel to Wuhan shows a

- 563 wide range of species - Lautropia, Cutibacterium, Haemophilus being most abundant - and
564 Campylobacter explaining diarrhea. *OSF Prepr.* 6–7 (2020). doi:10.31219/osf.io/jegwq
- 565 34. Larsen, J. M. The immune response to Prevotella bacteria in chronic inflammatory disease.
566 *Immunology* **151**, 363–374 (2017).
- 567 35. De Biasi, S. *et al.* Marked T cell activation, senescence, exhaustion and skewing towards TH17 in
568 patients with COVID-19 pneumonia. *Nat. Commun.* **11**, 1–17 (2020).
- 569 36. Faust, K. & Raes, J. CoNet app: Inference of biological association networks using Cytoscape.
570 *F1000Research* **5**, 1–14 (2016).
- 571 37. Klindworth, A. *et al.* Evaluation of general 16S ribosomal RNA gene PCR primers for classical and
572 next-generation sequencing-based diversity studies. *Nucleic Acids Res.* **41**, 1–11 (2013).
- 573 38. Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome data science using
574 QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).
- 575 39. Callahan, B. J. *et al.* DADA2: High resolution sample inference from Illumina amplicon data. *Nat.*
576 *Methods* **13**, 4–5 (2016).
- 577 40. Katoh, K., Misawa, K., Kuma, K. I. & Miyata, T. MAFFT: A novel method for rapid multiple
578 sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* **30**, 3059–3066 (2002).
- 579 41. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 - Approximately maximum-likelihood trees for
580 large alignments. *PLoS One* **5**, (2010).
- 581 42. Bokulich, N. A. *et al.* Optimizing taxonomic classification of marker-gene amplicon sequences with
582 QIIME 2's q2-feature-classifier plugin. *Microbiome* **6**, 1–17 (2018).
- 583 43. McDonald, D. *et al.* An improved Greengenes taxonomy with explicit ranks for ecological and
584 evolutionary analyses of bacteria and archaea. *ISME J.* **6**, 610–618 (2012).
- 585 44. Oksanen, J. *et al.* Community ecology package. (2013).

- 586 45. Lahti, L., Shetty, S. & et al. Tools for microbiome analysis in R. (2017).
- 587 46. McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive Analysis and
588 Graphics of Microbiome Census Data. *PLoS One* **8**, (2013).
- 589 47. Ning, D., Deng, Y., Tiedje, J. M. & Zhou, J. A general framework for quantitatively assessing
590 ecological stochasticity. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 16892–16898 (2019).
- 591 48. Melo, A. S. CommEcol: community ecology analyses. 1 (2016).
- 592 49. Dhariwal, A. *et al.* MicrobiomeAnalyst: A web-based tool for comprehensive statistical, visual and
593 meta-analysis of microbiome data. *Nucleic Acids Res.* **45**, W180–W188 (2017).
- 594 50. Team, R. C. R: A language and environment for statistical computing. (2020).
- 595 51. Shannon, P. *et al.* Cytoscape: A Software Environment for Integrated Models. *Genome Res.* 2498–
596 2504 (2003). doi:10.1101/gr.1239303.metabolite

597

598 **Acknowledgments**

599 We are thankful for the excellent clinical care of all physician and nurses at INER attending
600 COVID 19 patients.

601 **Author contributions**

602 AHT, JSH, RPP, and JAVP conceived and designed the project. OB, EG, EBV, CGP, and
603 VHAT collected the clinical data and constructed the database. AHT, FMN, CB, MM,
604 ARR, and JVP performed the experimental laboratory procedures. AHT and MC
605 performed the bioinformatics and statistical analyses. MTH, RS, SR, and JAVP
606 performed the interpretation of clinical data. AHT, FMN, MTH, SAR, RS, SR, RPP, and

607 JAVP wrote the manuscript. JAVP supervised the project and led the team. All authors
608 discussed the results and commented on the manuscript.

609

610 **Competing Interests Statement**

611 The authors declare that they have no competing interests.

612 **Funding**

613 This work was financially supported by Consejo Nacional de Ciencia y Tecnología
614 (CONACYT-FORDECYT 2020, grant "Caracterización de la diversidad viral y
615 bacteriana" to JAVP)

616

617 **Data availability**

618 The sequencing reads generated during the present study are available in the NCBI
619 Sequence Read Archive (SRA) accession PRNAJ726205.

620 **Figure legends**

621 **Table 1. Demographic data of the cohort.** Only upper respiratory samples (OPS and NPS) are
622 included in the information. Abbreviations: BMI= body mass index, DM2= Diabetes Mellitus Type
623 2. *Respiratory diseases: either asthma, COPD, or ILD. P values denote statistical significant
624 differences given by Wilcoxon rank-sum test (* < 0.05, ** < 0.005, *** < 0.0005).

625 **Figure 1. Main composition at phylum and genus level among severity levels for COVID-19**
626 **and controls. A:** median abundance of most abundant phyla in the analyzed groups. **B:** median
627 abundance of most abundant genera in the analyzed groups. Asterisks denote global statistical
628 differences given by Kruskal-Wallis test (*p*-values: * < 0.05, ** < 0.005, *** < 0.0005).

629 **Figure 2. Alpha diversity of the respiratory microbiota among severity levels for COVID-19**
630 **and controls.** Boxplot of the Shannon-Wiener index value for all analyzed groups. Asterisks denote
631 statistical significant differences given by Wilcoxon rank-sum test ($*p < 0.05$).

632 **Figure 3. Beta diversity of the respiratory microbiota among severity levels for COVID-19**
633 **and controls. A:** PCoA with weighted Unifrac distance and PERMANOVA result that test
634 differences in the community arrange among groups. Each ellipse represents an analyzed group
635 specified in the legend. **B:** Differentially abundant taxa obtained through LefSe analysis for each
636 group. Only features with a LDA score higher than 1.5 and a $p < 0.01$ were included. ASV:
637 Amplicon Sequence Variant.

638 **Figure 4. Correlation among clinical variables affecting survival probability and bacteria in**
639 **the respiratory microbiota. A:** Kaplan-Meier curves for the clinical variables with a statistical
640 significant difference in survival probability. Variables were classified into two categories
641 specified in the legend “factor”. All curves were constructed with hospitalization days and outcome
642 (either deceased or alive). **B:** Bacteria that are significantly depleted or enriched in samples with the
643 different risk factors for the clinical variables obtained trough Kaplan-Meier curves. Risk factor
644 (either high or low) corresponds to the result of the survival curves (panel A). ASV: Amplicon
645 Sequence Variant. APACHE: Acute Physiology and Chronic Health Evaluation, BUN: Blood Urea
646 Nitrogen.

647 **Figure 5. Network structure of the respiratory microbiota among severity levels for COVID-**
648 **19. A:** Co-occurrence/exclusion networks for mild, severe and fatal COVID-19. Each node
649 represents a microbial group at ASV level and each edge an interaction (either co-occurrence or co-
650 exclusion). Colors denote phylum identity. Number of samples used to construct the network (N),
651 number of nodes and number of edges are reported in the figure. **B:** Spider chart of the topological
652 metrics associated to each network.

653

654

655

656

657

658 **Table 1. Demographic data of the cohort**


659

	All (N= 95)	Healthy control (N=7)	COVID-19 Mild (N=37)	COVID-19 Severe (N=27)	COVID-19 Fatal (N=19)	Non-COVID-19 pneumonia (N=5)	p value
Age (years), median (IQR)	45 (21)	35 (18)	37 (18)	47(21)	58(16.5)	49(13)	6.75e-07 ***
Gender							
Female, n (%)	43 (45.2%)	5 (71.4%)	18 (48.6%)	12 (44%)	5 (26.3%)	3 (60%)	0.016 *
Male, n (%)	52 (54.7%)	2 (28.5%)	19 (51.3%)	15 (55.5%)	14 (73.6%)	2 (40%)	
Smoking, n (%)	15 (17%)	0	0	8 (29.6%)	7 (36.8%)	0	ns
NA	8	1	4	0	1	2	
BMI (kg/m²), median (IQR)	27.6(6.9)	26.2(2.6)	27.34(7.9)	28.9(4.6)	30.4 (9.8)	24.9(2.3)	0.05*
Obesity							
Not obese, n(%)	48 (50.5%)	5 (71.4%)	16 (43.2%)	16 (59.2%)	8 (42.1%)	3 (60%)	ns
Class I, n (%)	16 (61.5%)	0	9 (81.8%)	7 (77.7%)	2 (25%)	0	
Class II, n(%)	7 (29.9%)	0	1 (9%)	2 (22%)	4 (50%)	0	
Class III, n(%)	3 (11.5%)	0	1 (9%)	0	2 (25%)	0	
NA	21	2	12	2	3	2	
Comorbidities							
DM2, n (%)	15 (17%)	0	3 (8%)	7 (70.3%)	5 (26.3%)	0	ns
Hypertension, n (%)	15 (17%)	0	3 (8%)	4 (14.8%)	8 (42.1%)	0	ns
Respiratory disease*, n (%)	4 (4.5%)	0	3 (8%)	1 (3.7%)	1 (5.2%)	0	ns
NA	36	2	17	1	8	8	
Days after symptoms onset, n (IQR)	7 (6)	NA	5 (5)	6.5 (4.7)	5 (5)	10 (3)	0.01*
Antibiotic treatment, n (%)	50 (52.6%)	1 (14.2%)	11 (29.7%)	21 (77.7%)	15 (78.9%)	2 (40%)	0.002**
Symptoms							
Cough, n (%)	50 (52%)	2 (28.5%)	11 (29.7%)	20 (74%)	15 (78.9%)	2 (40%)	ns
Fever, n (%)	48 (50.5%)	2 (28.5%)	10 (27%)	19 (70.3%)	15 (78.9%)	2 (40%)	ns
Dyspnea, n (%)	42 (44%)	0	4 (10.8%)	18 (66.6%)	17 (89%)	3 (60%)	ns
Headache, n (%)	40 (42%)	1 (14.2%)	15 (40.5%)	13 (48%)	11 (57.8%)	0	0.001**
Myalgia, n (%)	38 (40%)	2 (28.5%)	12 (32.4%)	13 (48%)	10 (52.6%)	1 (20%)	0.003**
Arthralgia, n (%)	36 (37.8%)	2 (28.5%)	10 (27%)	13 (48%)	10 (52.6%)	1 (20%)	0.04*
Fatigue, n (%)	20 (21%)	0	3 (8%)	8 (29.6%)	9 (47%)	0	ns
Rhinorrhea, n (%)	26 (27.3%)	1 (14.2%)	6 (16%)	12 (44%)	6 (31.5%)	1 (20%)	ns
Chest pain, n (%)	13 (13.6%)	0	5 (13%)	4 (14.8%)	4 (21%)	0	ns
Diarrhea, n (%)	16 (16.8%)	0	4 (10.8%)	8 (29.6%)	4 (21%)	0	ns
Cyanosis, n (%)	7 (7.3%)	0	0	3(11%)	4 (21%)	0	ns
Vomiting, n (%)	5 (5.2%)	0	1 (2.7%)	3 (11%)	1 (5.2%)	0	ns
NA	105	0	70	12	0	23	

660

Figure 1

A



B









Figure 2





A



B







Figure 4

A Mild COVID-19

Severe COVID-19

Fatal COVID-19

Figure 5



B

